News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Novo Nordisk A/S (NVO) Hemophilia-A Treatment Wins EU Panel Backing


9/20/2013 7:24:28 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Novo Nordisk A/S (NOVOB) won backing from a European Union advisory panel for a hemophilia A medicine, a step forward in the Danish company’s plan to expand treatment offerings for the blood-clotting disorder. Turoctocog alfa was recommended by the European Medicines Agency’s Committee for Medicinal Products for Human Use, Novo Nordisk said in an e-mailed statement today. The European Commission, the EU’s executive arm, usually follows the panel’s recommendation.

Help employers find you! Check out all the jobs and post your resume.

Read at Bloomberg
Read at News Release
Read at Reuters


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES